加载中
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
前收盘价
US$44.05
−US$1.49 · -3.27%
盘中时间采用ET。市场数据可能有所延迟。
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
日内区间
当前US$44.05
52周区间
当前US$44.05
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
44
合理估值
情绪
63
看涨
风险
88
极高风险
动量
23
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
日内区间
当前US$44.05
52周区间
当前US$44.05
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 491.1万 USD | 1008.9万 USD | — | — |
| 毛利 | — | 491.1万 USD | 1008.9万 USD | — | — |
| 研究与开发 | 1952.2万 USD | 4641.8万 USD | 4943.2万 USD | 3519.8万 USD | 3069.8万 USD |
| 销售、一般及管理费用 | 1699.1万 USD | 1464.4万 USD | 1265万 USD | 1208.5万 USD | 1136.8万 USD |
| 营业费用 | 3651.3万 USD | 6106.2万 USD | 6208.2万 USD | 4728.3万 USD | 4206.6万 USD |
| 利息收入 | 113.7万 USD | 342.2万 USD | 455.7万 USD | 152.3万 USD | 11.9万 USD |
| 利息支出 | 9万 USD | 30.7万 USD | 48.3万 USD | 42万 USD | 34.5万 USD |
| 折旧和摊销 | 2.1万 USD | 4.6万 USD | 7万 USD | 7.4万 USD | 6.8万 USD |
| 营业利润 | −3651.3万 USD | −5615.1万 USD | −5199.3万 USD | −4728.3万 USD | −4206.6万 USD |
| 净利润 | −3896.6万 USD | −5303.6万 USD | −4791.9万 USD | −4618万 USD | −4229.2万 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI500.86万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM319.4万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF188.07万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO91.98万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC35.52万0.03%13.17亿 USD0.60%US$183+0.11%
iShares Russell 2000 Growth ETFIWO29.63万0.00%139.17亿 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS18.46万0.00%338.69亿 USD0.31%US$78.35+0.32%
Vanguard Russell 2000 Value ETFVTWV11.07万0.01%14亿 USD0.06%US$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
